Absci Corporation (ABSI)

$4.48

+0.1

(+2.28%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $4.39
    $4.53
    $4.48
    downward going graph

    2.12%

    Downside

    Day's Volatility :3.2%

    Upside

    1.1%

    downward going graph
  • $1.11
    $6.72
    $4.48
    downward going graph

    75.22%

    Downside

    52 Weeks Volatility :83.48%

    Upside

    33.33%

    downward going graph

Returns

PeriodAbsci CorporationSector (Health Care)Index (Russel 2000)
3 Months
-4.37%
6.5%
0.0%
6 Months
18.06%
7.1%
0.0%
1 Year
112.62%
9.8%
0.0%
3 Years
-81.35%
14.2%
-20.2%

Highlights

Market Capitalization
503.2M
Book Value
$2.13
Earnings Per Share (EPS)
-1.16
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
-2616.7%
Return On Assets TTM
-20.3%
Return On Equity TTM
-44.2%
Revenue TTM
5.3M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-29.2%
Gross Profit TTM
-39.8M
EBITDA
-78.8M
Diluted Eps TTM
-1.16
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.81
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Absci Corporation(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 78.57%

Current $4.48
Target $8.00

Company Financials

FY19Y/Y Change
Revenue
2.1M
-
Net Income
-6.8M
-
Net Profit Margin
-330.15%
-
FY20Y/Y Change
Revenue
4.8M
↑ 132.04%
Net Income
-14.6M
↑ 114.22%
Net Profit Margin
-304.79%
↑ 25.36%
FY21Y/Y Change
Revenue
4.8M
↑ 0.04%
Net Income
-101.0M
↑ 592.98%
Net Profit Margin
-2.1K%
↓ 1806.46%
FY22Y/Y Change
Revenue
5.7M
↑ 20.18%
Net Income
-104.9M
↑ 3.91%
Net Profit Margin
-1.8K%
↑ 285.88%
FY23Y/Y Change
Revenue
5.7M
↓ 0.5%
Net Income
-110.6M
↑ 5.4%
Net Profit Margin
-1.9K%
↓ 108.28%
Q4 FY22Q/Q Change
Revenue
1.6M
↓ 34.28%
Net Income
-19.5M
↓ 28.57%
Net Profit Margin
-1.3K%
↓ 99.9%
Q1 FY23Q/Q Change
Revenue
1.3M
↓ 18.5%
Net Income
-23.4M
↑ 19.95%
Net Profit Margin
-1.8K%
↓ 589.88%
Q2 FY23Q/Q Change
Revenue
3.4M
↑ 165.33%
Net Income
-41.7M
↑ 78.43%
Net Profit Margin
-1.2K%
↑ 602.77%
Q3 FY23Q/Q Change
Revenue
744.0K
↓ 77.9%
Net Income
-22.0M
↓ 47.22%
Net Profit Margin
-3.0K%
↓ 1718.52%
Q4 FY23Q/Q Change
Revenue
338.0K
↓ 54.57%
Net Income
-23.5M
↑ 7.05%
Net Profit Margin
-7.0K%
↓ 4009.8%
Q1 FY24Q/Q Change
Revenue
898.0K
↑ 165.68%
Net Income
-22.0M
↓ 6.67%
Net Profit Margin
-2.4K%
↑ 4518.88%
FY19Y/Y Change
Total Assets
19.5M
-
Total Liabilities
60.6M
-
FY20Y/Y Change
Total Assets
88.6M
↑ 354.88%
Total Liabilities
178.0M
↑ 193.58%
FY21Y/Y Change
Total Assets
426.2M
↑ 381.2%
Total Liabilities
60.1M
↓ 66.24%
FY22Y/Y Change
Total Assets
321.0M
↓ 24.68%
Total Liabilities
46.6M
↓ 22.46%
FY23Y/Y Change
Total Assets
234.5M
↓ 26.96%
Total Liabilities
58.3M
↑ 25.13%
Q4 FY22Q/Q Change
Total Assets
321.0M
↓ 5.42%
Total Liabilities
46.6M
↑ 0.32%
Q1 FY23Q/Q Change
Total Assets
295.8M
↓ 7.85%
Total Liabilities
41.8M
↓ 10.2%
Q2 FY23Q/Q Change
Total Assets
254.2M
↓ 14.08%
Total Liabilities
38.8M
↓ 7.38%
Q3 FY23Q/Q Change
Total Assets
236.3M
↓ 7.01%
Total Liabilities
39.9M
↑ 3.03%
Q4 FY23Q/Q Change
Total Assets
234.5M
↓ 0.79%
Total Liabilities
58.3M
↑ 46.02%
Q1 FY24Q/Q Change
Total Assets
274.9M
↑ 17.24%
Total Liabilities
34.8M
↓ 40.33%
FY19Y/Y Change
Operating Cash Flow
-6.0M
-
Investing Cash Flow
-1.1M
-
Financing Cash Flow
12.7M
-
FY20Y/Y Change
Operating Cash Flow
-11.0M
↑ 81.86%
Investing Cash Flow
-2.2M
↑ 99.36%
Financing Cash Flow
71.0M
↑ 458.58%
FY21Y/Y Change
Operating Cash Flow
-60.6M
↑ 452.4%
Investing Cash Flow
-67.4M
↑ 3003.5%
Financing Cash Flow
336.2M
↑ 373.69%
FY22Y/Y Change
Operating Cash Flow
-81.3M
↑ 34.23%
Investing Cash Flow
-127.0M
↑ 88.46%
Financing Cash Flow
5.2M
↓ 98.44%
Q4 FY22Q/Q Change
Operating Cash Flow
-18.6M
↓ 2.49%
Investing Cash Flow
-30.2M
↓ 61.66%
Financing Cash Flow
1.4M
↓ 251.25%
Q1 FY23Q/Q Change
Operating Cash Flow
-20.1M
↑ 8.35%
Investing Cash Flow
-27.3M
↓ 9.54%
Financing Cash Flow
-1.1M
↓ 179.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.2M
↓ 4.4%
Investing Cash Flow
70.2M
↓ 356.96%
Financing Cash Flow
-1.2M
↑ 10.51%

Technicals Summary

Sell

Neutral

Buy

Absci Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Absci Corporation
Absci Corporation
42.67%
18.06%
112.62%
-81.35%
-79.71%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Absci Corporation
Absci Corporation
NA
NA
NA
-0.81
-0.44
-0.2
NA
2.13
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Absci Corporation
Absci Corporation
Buy
$503.2M
-79.71%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Absci Corporation

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 338.0K → 898.0K (in $), with an average increase of 62.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -23.54M → -21.97M (in $), with an average increase of 7.1% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 267.9%

Institutional Holdings

  • FMR Inc

    13.10%

  • Redmile Group, LLC

    7.30%

  • Fred Alger Management, LLC

    6.55%

  • Vanguard Group Inc

    3.05%

  • ARK Investment Management LLC

    2.90%

  • Millennium Management LLC

    1.57%

Company Information

Organization
Absci Corporation
Employees
155
CEO
Mr. Sean McClain
Industry
Services

Discover More

FAQs